Men | 15 (83%) | 16 (88%) |
Age (years) | 45 (37–55) | 47 (36–58) |
Homosexuals | 13 (72%) | 11 (61%) |
Heterosexuals | 4 (22%) | 5 (28%) |
Unknown factors | 1 (6%) | 2 (11%) |
Duration of documented seropositivity (months) | 25 (11–32) | 28 (14–43) |
CD4 count (cells/mm3) | 330 (175–653) | 350 (160–730) |
Plasma HIV RNA (log10)copies/ml | 4.3 (3.3–5.5) | 4.5 (3.5–6.1) |
Positivity for HBV/HCV | 3 (17%) | 2 (11%) |
CDC class | | |
A1 | 3 (17%) | 2 (11%) |
A2 | 12 (66%) | 13 (72%) |
A3 | 3 (17%) | 3 (17%) |
Antiretroviral drug given at enrolment | |
Combination (ritonavir + indinavir) | 6 (33%) | 7 (39%) |
Nelfinavir | 3 (17%) | 2 (11%) |
Zidovudine | 18 (100%) | 18 (100%) |
Didanosine | 18 (100%) | 18 (100%) |
Nevirapine | 3 (17%) | 2 (11%) |
Efavirenz | 6 (33%) | 7 (39%) |
Cardiopulmonary haemodynamic parameters | |
Right atrial pressure (mm Hg) | 11 (6–18) | 12 (7–17) |
mPAP (mm Hg) | 52 (42–63) | 53 (44–65) |
PCWP (mm Hg) | 7.5 (5–8) | 7.7 (6–9) |
PVR (dyn·s·cm−5) | 770 (610–930) | 780 (625–950) |
Cardiac index (l/min/m2) | 2.7 (2.2–3.3) | 2.6 (2–3.2) |
NYHA class | | |
III | 17 (94%) | 16 (89%) |
IV | 1 (6%) | 2 (11%) |
Six-minute walk distance (m) | 270 (197–343) | 265 (205–325) |
Duration of symptoms (months) | 12 (6–18) | 11 (5–16) |
Concomitant PAH treatment | | |
Anticoagulants | 1 (6%) | 2 (11%) |
Oxygen | 1 (6%) | 2 (11%) |